Researchers looked at the cost of a program in which staff test all patients for MRSA and then isolate carriers. They found such a program that tested patients for MRSA in the nose would cost a hospital $103,000 per 10,000 hospital admissions while preventing nearly three MRSA infections.
The cost of a program that targeted only high-risk patients also outweighed potential savings from preventing infections, the researchers found. Nares testing prevented fewer than one infection per 1,000 high-risk admissions and created a loss of $36,899.
“Although more extensive MRSA testing and isolation could prevent hospital-acquired MRSA infections, we found the cost of such a program far exceeds any savings to the hospital,” said James McKinnell, MD, a Los Angeles Biomedical Research Institute lead researcher. “Our results are surprising because we know that preventing MRSA infections is better for the healthcare system as a whole, but the rewards of this effort do not seem to come back to the hospital in a meaningful way. In today’s constrained healthcare environment, hospitals must either be given better financial incentives or better and more cost-effective infection prevention strategies to provide the greatest benefit to the people they serve.”
More articles on MRSA:
Shark skin-inspired surface limits MRSA spread, study shows
Viewpoint: Are current hospital MRSA control policies effective enough?
MRSA colonization not limited to nose: Study
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
